Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

(2016) Alberico L. Catapano et al.   EUROPEAN HEART JOURNAL

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

(2016) Nicholas J Viney et al.   LANCET

Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA

(2016) Johannes Kettunen et al.   Nature Communications

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study

(2015) Sotirios Tsimikas et al.   LANCET

Net Reclassification Improvement: Computation, Interpretation, and Controversies

(2014) Maarten J.G. Leening et al.   ANNALS OF INTERNAL MEDICINE

BiomarCaRE: rationale and design of the European BiomarCaRE project including 300,000 participants from 13 European countries

(2014) Tanja Zeller et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Discrimination and Net Reclassification of Cardiovascular Risk With Lipoprotein(a)

(2014) Peter Willeit et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)

(2012) et al.   EUROPEAN HEART JOURNAL

Combining individual participant and aggregated data in a meta-analysis with correlational studies

(2012) Terri Pigott et al.   Research Synthesis Methods

Lipoprotein(a) as a cardiovascular risk factor: current status

(2010) Børge G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Management of Lp(a)

(2010) W. Virgil Brown et al.   Journal of Clinical Lipidology

Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers

(2010) Michael J. Pencina et al.   STATISTICS IN MEDICINE

Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction

(2009) Pia R. Kamstrup   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality

(2009)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Lipoprotein(a) Levels and Risk of Future Coronary Heart DiseaseLarge-Scale Prospective Data

(2008) Anna Bennet   ARCHIVES OF INTERNAL MEDICINE

Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population

(2007) Pia R. Kamstrup et al.   CIRCULATION